

# Dermatology

## 2020 Clinical Integration (CI) Pharmacy Program

The following are Key Recommendations to help increase Generic Prescribing:

- Reinforce the value of generics with patients!
- Indicate "May Substitute" on prescriptions!
- Prescribe 90 day supplies of maintenance (chronic use) medications.

- Use medications with an available generic such as:

- generic Acanya (clindamycin 1.2%/benzoyl peroxide 2.5% gel)
- generic BenzaClin (clindamycin 1%/benzoyl peroxide 5% gel)
- generic BenzaClin Pump (clindamycin 1%/benzoyl peroxide 5% gel)
- generic Benzamycin (erythromycin 3%/benzoyl peroxide 5% gel)
- Differin Gel 0.1% OTC
- generic Differin (adapalene 0.1% gel)
- generic Differin (adapalene 0.3% gel)
- generic DUAC or Neuac (clindamycin 1.2%/benzoyl peroxide 5% gel)
- generic Epiduo (adapalene 0.1%/benzoyl peroxide 2.5% gel)
- generic Veltin/Ziana (clindamycin 1.2%/tretinoin 0.025% gel)

*Use brand Altreno, Azelex, Epiduo Forte, and Onexton as secondary options.*

### Now available - generic Acanya Gel!

- Use generic doxycycline hyclate, generic doxycycline monohydrate, generic Adoxa (doxycycline monohydrate), generic Doryx (doxycycline hyclate ER tabs), generic Dynacin/Minocin (minocycline HCl), generic Monodox (doxycycline monohydrate), or generic Solodyn (minocycline HCl ER tabs).

**A 30 day supply of brand Seysara (sarecycline HCl tab) has a list price of \$1,093!**

**A 30 day supply of brand Ximino (minocycline HCl ER cap) has a list price of \$839.00!**

- Use Allegra OTC, Claritin OTC, Xyzal OTC, or Zyrtec OTC as initial therapeutic options. Use generic Clarinex (desloratadine) or generic Xyzal (levocetirizine) as secondary options.
- Use Baza OTC (miconazole 2% cream), generic Extina (ketoconazole), generic Lamisil (terbinafine), generic Loprox (ciclopirox), generic Lotrimin (clotrimazole), Lotrimin AF OTC (miconazole), Lotrimin Ultra AF OTC (butenafine), generic Mentax (butenafine 1%),

generic Mycostatin (**nystatin**), generic Naftin 1% or 2% cream or gel (**naftifine**), generic Nizoral (**ketconazole**), generic Oxistat (**oxiconazole 1% cream**), or generic Spectazole (**econazole**). *Reserve Ertaczo, Exelderm, Luzu (and generic Luzu), and Oxistat Lotion as secondary options.*

---

- **High brand copays may result in the patient not obtaining the medication!**
- **Non-Formulary medication prescribing may result in additional call-backs or faxes to the office from pharmacies, pharmacy benefit managers, and patients!**
- Use **Inflextra (influximab-dyyb)** [biosimilar Remicade] or **Renflexis (influximab-abda)** [biosimilar Remicade] as alternatives to **Remicade**.

**The biosimilars are approximately 35% less expensive than brand Remicade**

(Note: Inflextra and Renflexis are not approved for Pediatric Ulcerative Colitis – a patent expiration issue)

## Biosimilars – Key Takeaways

- Biosimilars are not exact copies of the brand products - **“Not generics.”**
  - They contain a similar protein/chemical structure and produce similar biological responses.
- The U.S FDA has a process in place to evaluate and approve biosimilars.
  - They **may have** different FDA approved indications compared with the brand.
  - The **“Interchangeable”** designation **will allow** for substitution – like generics
- Most major brand manufacturers will offer a line of biosimilar medications.
- They may be priced 10-35% or more below the brand.
- PBM and insurer formularies **may** or **may not** include the biosimilar **and** the brand.
- PBMs, insurers, and payers are “counting on” biosimilars to help ease the 15-20% year over year increase in specialty drug spend.
- Physicians will need to prescribe the “follow on” or biosimilar by its name i.e., **Inflextra (influximab-dyyb)** and **Renflexis (influximab-abda)** etc. and be aware of what indications the medication is approved e.g.; **Inflextra and Renflexis are not approved for Pediatric Ulcerative Colitis – a patent expiration issue**
- Many biosimilars will have coupons and patient assistance (\$\$) programs just like the brands.

Reference:

<http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/>

The above applies to **outpatient** prescribing only!